Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Retrieved on:
Thursday, October 19, 2023
Nexus, Markov, Pharmacy, OBR, Academy of Managed Care Pharmacy, Observation, Fungal infection, HIV, News, Acquisition, Nursing care plan, Journal, QALY, ART, Quality-adjusted life year, Database, Clinical trial, Abstract, HTE, Ibalizumab, Health, ICER, AMCP, SMR, EHR, Bronze medal, Bias, TSX, Health care, Pharmaceutical industry
The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.
Key Points:
- The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.
- The analysis encompassed numerous costs, including those for treatment acquisition and administration, monitoring, adverse events, opportunistic infections, and terminal care.
- Mortality assumptions and health-state utility values were based on disease-specific published literature and clinical trial data.
- Over a lifetime horizon, the addition of ibalizumab to OBR increased the time patients’ HIV remained undetectable (less than 50 copies/ml) or suppressed (between 50 and 200 copies/ml).